Here’s what you should know:
1. Exact Sciences increased sales 148 percent year-over-year for the fourth quarter and 168 percent year-over-year for fiscal year 2017.
2. Exact Sciences completed 176,000 Cologuard tests during the fourth quarter of 2017, an increase of 115 percent, year-over-year.
3. For the year, Exact Sciences completed a total of 571,000 Cologuard tests, a 134 percent increase over 2016.
4. Exact Sciences CEO Kevin Conroy said in a release, “An increasing number of people are being screened for colon cancer with our accurate, non-invasive test. As demand for Cologuard strengthens, we will continue to invest in our team, facilities and infrastructure to support the company’s long-term growth.”
5. Exact Sciences will report its 2017 financial results in February.
More articles on gastroenterology:
GI leader to know: Dr. Alexandra Read of Puget Sound Gastroenterology
OrphoMed taps GI expert Dr. Mark Sostek for CMO position — 3 insights
Takeda to acquire TiGenix for $628M — 4 insights
